
American Academy of Allergy, Asthma & Immunology: AAAAI
According to data presented at AAAAI, berotralstat demonstrated a well tolerated safety profile and early and sustained reductions in monthly HAE attacks among patients aged 2 to under 12 years.









.jpeg?w=350&fit=crop&auto=format)









